OptimizeRx (NASDAQ:OPRX) Announces Earnings Results, Beats Estimates By $0.05 EPS

Key Points

• OptimizeRx beat quarterly earnings expectations: The company reported $0.16 in EPS, $0.05 above consensus, while revenue of $20.50 million modestly exceeded estimates of $20.20 million.
• Shares rose to $7.04 following the results, though the stock remains well below its 12-month high of $22.25. OptimizeRx has a $132.11 million market capitalization and a strong 5.37 current and quick ratio.
• Analyst sentiment remains moderately positive: Six analysts rate the stock Buy, two rate it Hold and one rates it Sell, producing a consensus “Moderate Buy” rating and a $13.43 price target; institutional investors own 76.47% of shares.

OptimizeRx (NASDAQ:OPRX - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.16 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.05, FiscalAI reports. The business had revenue of $20.50 million during the quarter, compared to analysts' expectations of $20.20 million. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%.

OptimizeRx Stock Performance

Shares of OptimizeRx stock traded up $0.12 on Wednesday, hitting $7.04. The stock had a trading volume of 324,917 shares, compared to its average volume of 422,567. The stock has a market cap of $132.11 million, a price-to-earnings ratio of 20.11 and a beta of 1.08. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.16. OptimizeRx has a twelve month low of $4.54 and a twelve month high of $22.25. The business's 50 day moving average is $5.93 and its two-hundred day moving average is $6.77.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on OPRX. Weiss Ratings cut OptimizeRx from a "sell (d+)" rating to a "sell (d)" rating in a research report on Thursday, May 14th. Zacks Research cut OptimizeRx from a "strong-buy" rating to a "hold" rating in a research note on Monday, May 4th. UBS Group set a $10.00 price target on OptimizeRx in a report on Wednesday, May 13th. Wall Street Zen cut shares of OptimizeRx from a "strong-buy" rating to a "buy" rating in a research report on Monday, July 20th. Finally, Lake Street Capital decreased their price objective on shares of OptimizeRx from $20.00 to $11.00 and set a "buy" rating on the stock in a report on Wednesday, May 13th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $13.43.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in OPRX. Millennium Management LLC bought a new position in OptimizeRx during the 4th quarter worth $535,000. Inspire Investing LLC bought a new stake in shares of OptimizeRx during the 4th quarter worth $1,175,000. Engineers Gate Manager LP acquired a new stake in shares of OptimizeRx in the 4th quarter valued at approximately $228,000. Boothbay Fund Management LLC grew its stake in shares of OptimizeRx by 53.1% during the fourth quarter. Boothbay Fund Management LLC now owns 73,488 shares of the company's stock worth $901,000 after buying an additional 25,502 shares during the last quarter. Finally, Bridgeway Capital Management LLC grew its position in OptimizeRx by 16.9% during the 4th quarter. Bridgeway Capital Management LLC now owns 69,029 shares of the company's stock worth $846,000 after acquiring an additional 10,000 shares during the last quarter. Institutional investors own 76.47% of the company's stock.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company's core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source